Abstract 2252P
Background
KRAS activating mutations are the most common oncogenic drivers and are correlated with radioresistance of multiple cancers including NSCLC and colorectal cancers. Multiple KRAS inhibitors were developed recently such as MRTX849 (Adagrasib,Mirati Therapeutics) showing promising clinical efficacy in early phase trials. However, only scarce data exploring the combination of radiotherapy (RT) and a KRAS inhibitor in KRASG12C mutated tumors are available. We explore the efficacy of the association between RT and MRTX1257, a selective and covalent KRASG12C inhibitor analogous to MRTX849, in animal models of cancer.
Methods
We assessed in vitro the efficacy of the combination MRTX1257 at various concentrations and different RT doses in CT26 WT and CT26 KRASG12C+/+ cell lines using clonogenic survival assays.We then explored the combination in LL2 NRAS-/- and WT cell lines. Subsequently, we explored the efficacy of combination MRTX1257 and RT in athymic nude mice bearing CT26 KRASG12C+/+ tumors and in immunocompetent BALB/c mice bearing subcutaneous CT26 WT or CT26 KRASG12C+/+ tumors.On day of randomization (D-1 before RT), D+1 and D+3 after RT, mice received oral MRTX1257 at 50 mg/kg dose. At D0, mice randomized into RT only and combination groups received 1x 6 Gy to the tumor. On D4 post RT, tumours were collected for IHC and flow cytometry analysis of the tumour microenvironment.
Results
MRTX1257 increased the cytotoxic effect of RT in different KRAS G12C mutated cell lines and murine tumors, but not in their KRAS G12C wild type counterparts. In vitro and in vivo radio-sensitizing effects were observed in a time and dose dependent manner. The use of RT and MRTX1257 in BALB/c mice bearing CT26 KRASG12C+/+ tumors resulted in a 20% cure rate. Tumor microenvironment analysis of murine CT26 KRASG12C+/+ tumors following RT and MRTX1257 showed an increase in conventional CD4+ T cells, DCs type 2 and inflammatory monocytes. Expression of PD-L1 was reduced within tumor and myeloid cells, illustrating TME polarization towards a pro-inflammatory phenotype following the combination.
Conclusions
This work constitutes a first step towards new combinatorial approaches involving RT and MRTX1257 in KRAS G12C mutated cancers, with the aim of providing new therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mirati Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08